Mediwatch plc, through its subsidiaries, engages in the development and marketing of medical devices used in the diagnosis of urological disorders and the detection of early prostate cancer. It offers ultrasound products that include Portascan+, a portable real-time ultrasound bladder scanner; and Multiscan PVR, a portable real-time bladder scanner for scanning bladder volume. The company also provides urodynamics products, which consist of Urodyn+, a wireless uroflow meter; Portaflow and Portaflow advanced, which provide uroflow data and tracings for male, female, and pediatric patients in various point-of-care environments; Clinic Sensic and Portable Sensic systems, which are urodynamics s...
Rugby, CV21 1TQ
Founded in 1996
Mediwatch plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended April 30, 2013
Jun 3 13
Mediwatch plc announced unaudited consolidated earnings results for the six months ended April 30, 2013. For the six months, the company’s revenue was £4,911,000 against £5,084,000 a year ago. Profit from operating activities was £161,000 against £78,000 a year ago. Profit before taxation was £121,000 against £39,000 a year ago. Profit for the period attributable to the equity shareholders was £121,000 or 0.09 pence per basic and diluted share against £39,000 or 0.03 pence per basic and diluted share a year ago. Net cash used in operating activities was £61,000 against net cash from operating activities of £163,000 a year ago. Purchase of property, plant & equipment was £52,000 for the six months ended March 31, 2013. Purchase of intangible fixed assets was £263,000 against £363,000 a year ago. The group achieved an EBITDA of £311,000 for the six months to April 30, 2013 compared to £245,000 for the first half year 2012. Profit is very slightly ahead of the board's expectations at this stage. Cash flow was down due to increasing working capital requirement in the USA from the increasing sales.